Global Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Forecast 2024-2030- Product Image

Sale

Global Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Forecast 2024-2030

Report
198 Pages
March 2024
Region: Global
360iResearch™
ID: 5674674

UP TO €846EUR$875USD£717GBP OFF until Dec 31^st 2024

The Progressive Familial Intrahepatic Cholestasis Treatment Market size was estimated at USD 83.94 million in 2023, USD 86.35 million in 2024, and is expected to grow at a CAGR of 4.26% to reach USD 112.43 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Progressive Familial Intrahepatic Cholestasis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Progressive Familial Intrahepatic Cholestasis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Akorn, Inc., Albireo Pharma, Inc., Glenmark Pharmaceuticals Limited, Mirum Pharmaceuticals, Novartis AG, Par Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Vivet Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Cholestyramine
- Rifampicin
- Ursodeoxycholic Acid
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
End-Users
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Progressive Familial Intrahepatic Cholestasis Treatment Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Progressive Familial Intrahepatic Cholestasis Treatment Market?
What are the technology trends and regulatory frameworks in the Progressive Familial Intrahepatic Cholestasis Treatment Market?
What is the market share of the leading vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market?
Which modes and strategic moves are suitable for entering the Progressive Familial Intrahepatic Cholestasis Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in prevalence of geriatric population and liver disorder
5.1.1.2. Rise in research and development of novel drugs for progressive familial intrahepatic cholestasis (PFIC) type 2 treatment
5.1.1.3. Increase in drug approvals from regulatory bodies
5.1.2. Restraints
5.1.2.1. High cost of treatments and failure of therapies
5.1.3. Opportunities
5.1.3.1. Development of partial internal biliary drainages (PIBD)
5.1.3.2. Development of novel odevixibat therapies to treat PFIC
5.1.4. Challenges
5.1.4.1. Recurrence of PFIC Post liver transplantation
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

6.1. Introduction
6.2. Cholestyramine
6.3. Rifampicin
6.4. Ursodeoxycholic Acid

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Specialty Clinics

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. AbbVie, Inc.
13.1.2. Akorn, Inc.
13.1.3. Albireo Pharma, Inc.
13.1.4. Glenmark Pharmaceuticals Limited
13.1.5. Mirum Pharmaceuticals
13.1.6. Novartis AG
13.1.7. Par Pharmaceuticals, Inc.
13.1.8. Sanofi S.A.
13.1.9. Teva Pharmaceutical Industries Ltd.
13.1.10. Viatris Inc.
13.1.11. Vivet Therapeutics
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET DYNAMICS
FIGURE 7. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 10. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 14. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 27. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 30. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 44. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 47. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 53. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 71. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 84. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 87. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 90. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 93. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 99. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 108. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 111. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 114. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 126. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 135. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 144. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

AbbVie, Inc.
Akorn, Inc.
Albireo Pharma, Inc.
Glenmark Pharmaceuticals Limited
Mirum Pharmaceuticals
Novartis AG
Par Pharmaceuticals, Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Vivet Therapeutics

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	198
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 86.35 Million
Forecasted Market Value ( USD ) by 2030	$ 112.43 Million
Compound Annual Growth Rate	4.2%
Regions Covered	Global
No. of Companies Mentioned	11

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,763GBP €3625EUR$3,749USD£3,070GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,500GBP €4593EUR$4,749USD£3,889GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,238GBP €5560EUR$5,749USD£4,708GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£4,975GBP €6527EUR$6,749USD£5,527GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,449GBP €8461EUR$8,749USD£7,165GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Progressive Familial Intrahepatic Cholestasis (PFIC) - Pipeline Insight, 2024

Primary Sclerosing Cholangitis - Pipeline Insight, 2024

Global Alport Syndrome Market by Product (Diagnosis, Treatments), Genetic Type (Autosomal Dominant Alport Syndrome, Autosomal Recessive Alport Syndrome, X-linked Alport Syndrome), End-Use - Forecast 2024-2030

Global Polycystic Kidney Disease Drugs Market by Type (ADPKD, ARPKD), Treatment (Medication, Surgery), Diagnosis, Distribution Channels, End-User - Forecast 2024-2030

Primary Sclerosing Cholangitis Market Report and Forecast 2024-2032